SEHTA and Psephos Biomedica are running their next workshop on IVD New IVDR CE Marking.
This seminar will provide you insights into the key regulatory changes of the IVDR, to help you to prepare your organisation and your devices for IVDR compliance.
Date: Thursday 21st November 2019
Venue: Hempsons, 100 Wood Street, London, EC2V 7AN
Time: 10:30 – 15.30
Cost: SEHTA members fee: £240 + VAT / Non-Members: £280 + VAT per delegate
Not a member of SEHTA? It’s free to join – just click here
The Invitro Diagnostic Regulations are in transition and companies need to understand and prepare for these significant changes. Attendees will gain an understanding of:
- The new IVD regulations (EU 2017/746), Device Classification and Key Time Lines
- Significant differences between the current directive (98/79/EC) and the new IVD Regulations
- The role and status of Notified Bodies
- Outline of the Technical Documentation including Labelling and EUDAMED
- Outline of the Quality System requirements
- Outline of the Performance requirements/Clinical evidence
- Outline of Post Market Surveillance requirements
- Interact with fellow practitioners and presenter during the Q&A
The European Union’s Regulation on IVD medical devices 2017/746 (IVDR) came into force on 25 May 2017 and is currently in implementation. It will replace Directive 98/79/EC on IVD medical devices (IVDD) and there are only 2 ½ years left until the end of the transition.
Manufacturers of new IVD devices and devices currently approved under the current Directive will have to comply to IVDR from May 2022 onwards. This means they must comply with the new conformity assessment procedure for their device and quality system in order to CE-mark their devices and place them on the EU market. For products currently certified by a notified body – provided certain MDR requirements are met – the transition period may be extended until 26 May 2024.
New or stricter requirements of the IVDR will be challenging and have a significant impact on manufacturers and all other stakeholders. Changes affect areas such as classification of IVD devices, conformity assessment procedures, performance/clinical evidence, post market surveillance, labelling and registration.
The majority of devices will be reclassified and require Notified Body conformity assessment. For existing IVD manufacturers to meet the May 2022 deadline they will need to understand what is required and have a plan to address their current gap. For new manufacturers and devices understanding the new timelines, resourcing and expertise requirements will be crucial to success.
Not for: Pharma this is IVD Only.
Target Market: Executives, product owners, medical officers, regulatory and quality specialists within a company that need to understand the overall requirements for their Invitro Diagnostic Devices to enable them to place a device on the market and to maintain access. All company sizes will find it useful.
|10:30 -10:45||Registration & Refreshments|
|10:45 – 10:55||Welcome & Introduction
|Neil Roberts, COO, SEHTA|
|10:55 – 12:15||IVDR/ Classification/Notified Bodies/ IVD-IVDR differences||Jacques Du Preez, Director
|12:15 – 13:00||Networking Lunch Break|
|13:00 – 14:15||Technical documents and Performance reporting/clinical evidence||Jacques Du Preez, Director
|14:15 – 14:35||Refreshment Break|
|14:35 – 15:20||Quality System Requirements / Post Market Surveillance/ FDA||Jacques Du Preez, Director
|15:20 – 15:30||Q&A||All|
|15:30||Close||Neil Roberts, COO, SEHTA|
Places are limited so register today
Please note – The organisers reserve the right to decline registrations based on review. All applicants will be notified by email if they have been accepted for a place no later than Friday 8th November.